Team
Bruno ségui – nathalie andrieu

MELASPHINX :

Ceramide metabolism in melanoma: from basic mechanisms to immunotherapy

General presentation of the team

Our team was created in 2011, under the direction of Prof. Thierry Levade. Since 2021, it has been led by Prof. Bruno Ségui and Dr. Nathalie Andrieu-Abadie. It is composed of 26 members, including 3 researchers, 2 assistant professors, 4 professors, 5 engineers/technicians, 2 hospital practitioners, 2 post-doctoral fellows, 5 PhD students and 3 master trainees per year.

Scientific objectives

Cutaneous melanoma is the leading cause of death among skin cancers. Immune checkpoint inhibitors (ICI) have revolutionised the therapeutic management of patients with advanced cutaneous melanoma. However, only half of patients respond sustainably to ICIs due to primary or adaptive resistance mechanisms. Abnormal lipid profiles are often associated with an altered metabolic phenotype in tumour cells, which is a hallmark of cancer. The scientific activity of our team aims to better understand the molecular mechanisms by which alterations in ceramide metabolism contribute to melanoma progression, immune escape and resistance to ICI in preclinical models of melanoma. Through existing collaborations between researchers and clinicians, our ambition is to transfer our basic scientific findings to the clinic with the aim of identifying new biomarkers to predict response to ICIs and to propose appropriate treatments for patients with advanced melanoma. In addition, our research over the past 5 years has provided the scientific rationale for three clinical trials in 150 patients with advanced melanoma treated with immunotherapy. These trials are under the responsibility of Prof. Nicolas Meyer, oncodermatologist at the IUCT.

Our ultimate goal is to reprogram the metabolism of ceramide to improve therapeutic efficacy.

The specificities
of our research axis

Melanoma

Metabolism

Ceramide

Immunotherapy

TNF

Research
projects

THE TEAM’S
FOCUS

live

Le Pr Buno Segui (@melasphinx) et le Pr Nicolas Meyer présentent leur projet MELANICa qui a pour objectif d’évaluer le bénéfice potentiel des anti-TNF sur la réponse immunitaire anti-cancéreuse chez des #patients atteints de #mélanome.
En savoir plus 👉 http://bit.ly/3bQQu0U

Load More...

Scientific productions

PUBLICATIONS 2022
Fougerat, Anne, Gabriele Schoiswohl, Arnaud Polizzi, Marion Régnier, Carina Wagner, Sarra Smati, Tiffany Fougeray, et al. “ATGL-Dependent White Adipose Tissue Lipolysis Controls Hepatocyte PPARα Activity.” Cell Reports 39, no. 10 (June 7, 2022): 110910. https://doi.org/10.1016/j.celrep.2022.110910.
Germain, Dominique P., Thierry Levade, Eric Hachulla, Bertrand Knebelmann, Didier Lacombe, Vanessa Leguy Seguin, Karine Nguyen, Esther Noël, and Jean-Pierre Rabès. “Challenging the Traditional Approach for Interpreting Genetic Variants: Lessons from Fabry Disease.” Clinical Genetics 101, no. 4 (April 2022): 390–402. https://doi.org/10.1111/cge.14102.
Dummer, Reinhard, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul D. Nathan, et al. “Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, January 14, 2022, JCO2101601. https://doi.org/10.1200/JCO.21.01601.
PUBLICATIONS 2021
Montfort, Anne, Mathieu Virazels, Céline Colacios, Nicolas Meyer, and Bruno Ségui. “Combining TNF Blockade with Immune Checkpoint Inhibitors in Patients with Cancer.” Nature Reviews. Rheumatology 17, no. 9 (September 2021): 577. https://doi.org/10.1038/s41584-021-00653-8.
Marcheteau, Elie, Thomas Farge, Michaël Pérès, Guillaume Labrousse, Julie Tenet, Stéphanie Delmas, Maud Chusseau, et al. “Thrombospondin-1 Silencing Improves Lymphocyte Infiltration in Tumors and Response to Anti-PD-1 in Triple-Negative Breast Cancer.” Cancers 13, no. 16 (August 12, 2021): 4059. https://doi.org/10.3390/cancers13164059.
Rabiller, Lise, Virginie Robert, Adèle Arlat, Elodie Labit, Marielle Ousset, Marie Salon, Agnès Coste, et al. “Driving Regeneration, Instead of Healing, in Adult Mammals: The Decisive Role of Resident Macrophages through Efferocytosis.” NPJ Regenerative Medicine 6, no. 1 (August 3, 2021): 41. https://doi.org/10.1038/s41536-021-00151-1.
Montfort, Anne, Florie Bertrand, Julia Rochotte, Julia Gilhodes, Thomas Filleron, Jean Milhès, Carine Dufau, et al. “Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy.” Cancer Immunology Research 9, no. 5 (May 2021): 568–82. https://doi.org/10.1158/2326-6066.CIR-20-0342.
PUBLICATIONS 2020
Montfort, Anne, Thomas Filleron, Mathieu Virazels, Carine Dufau, Jean Milhès, Cécile Pages, Pascale Olivier, et al. “Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase 1b Clinical Trial.” Clinical Cancer Research, December 3, 2020, clincanres.3449.2020. https://doi.org/10.1158/1078-0432.CCR-20-3449.
Pellerin, Laurence, Lorry Carrié, Carine Dufau, Laurence Nieto, Bruno Ségui, Thierry Levade, Joëlle Riond, and Nathalie Andrieu-Abadie. “Lipid Metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives.” Cancers 12, no. 11 (October 27, 2020): 3147. https://doi.org/10.3390/cancers12113147.
Carrié, Lorry, Mathieu Virazels, Carine Dufau, Anne Montfort, Thierry Levade, Bruno Ségui, and Nathalie Andrieu-Abadie. “New Insights into the Role of Sphingolipid Metabolism in Melanoma.” Cells 9, no. 9 (August 26, 2020): 1967. https://doi.org/10.3390/cells9091967.
Dubot, Patricia, Leonardo Astudillo, Nicole Therville, Frédérique Sabourdy, Jérôme Stirnemann, Thierry Levade, and Nathalie Andrieu-Abadie. “Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses.” Cancers 12, no. 2 (February 18, 2020). https://doi.org/10.3390/cancers12020475.
Imbert, Caroline, Anne Montfort, Marine Fraisse, Elie Marcheteau, Julia Gilhodes, Elodie Martin, Florie Bertrand, et al. “Resistance of Melanoma to Immune Checkpoint Inhibitors Is Overcome by Targeting the Sphingosine Kinase-1.” Nature Communications 11, no. 1 (January 23, 2020): 437. https://doi.org/10.1038/s41467-019-14218-7.
PUBLICATIONS 2019
Montfort, Anne, Carine Dufau, Céline Colacios, Nathalie Andrieu-Abadie, Thierry Levade, Thomas Filleron, Jean-Pierre Delord, Maha Ayyoub, Nicolas Meyer, and Bruno Ségui. “Anti-TNF, a Magic Bullet in Cancer Immunotherapy?” Journal for Immunotherapy of Cancer 7, no. 1 (November 14, 2019): 303. https://doi.org/10.1186/s40425-019-0802-y.
Alaeddine, Mohamad, Mélissa Prat, Véréna Hauke Poinsot, Valérie Gouazé-Andersson, Hélène Authier, Etienne Meunier, Lise Lefèvre, et al. “IL13-Mediated Dectin-1 and Mannose Receptor Overexpression Promotes Macrophage Antitumor Activities through Recognition of Sialylated Tumor Cells.” Cancer Immunology Research, January 4, 2019. https://doi.org/10.1158/2326-6066.CIR-18-0213.
Leclerc, Justine, David Garandeau, Charlotte Pandiani, Céline Gaudel, Karine Bille, Nicolas Nottet, Virginie Garcia, et al. “Lysosomal Acid Ceramidase ASAH1 Controls the Transition between Invasive and Proliferative Phenotype in Melanoma Cells.” Oncogene 38, no. 8 (2019): 1282–95. https://doi.org/10.1038/s41388-018-0500-0.
Garandeau, David, Justine Noujarède, Justine Leclerc, Caroline Imbert, Virginie Garcia, Marie-Lise Bats, Florian Rambow, et al. “Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas.” Molecular Cancer Therapeutics 18, no. 2 (2019): 289–300. https://doi.org/10.1158/1535-7163.MCT-17-1141.
Montfort, Anne, Céline Colacios, Thierry Levade, Nathalie Andrieu-Abadie, Nicolas Meyer, and Bruno Ségui. “Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy.” Frontiers in Immunology 10 (2019): 2515. https://doi.org/10.3389/fimmu.2019.02515.
Montfort, Anne, Céline Colacios, Thierry Levade, Nathalie Andrieu-Abadie, Nicolas Meyer, and Bruno Ségui. “The TNF Paradox in Cancer Progression and Immunotherapy.” Frontiers in Immunology 10 (2019): 1818. https://doi.org/10.3389/fimmu.2019.01818.
Bilal, Fatima, Anne Montfort, Julia Gilhodes, Virginie Garcia, Joëlle Riond, Stéphane Carpentier, Thomas Filleron, et al. “Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma.” Frontiers in Pharmacology 10 (2019): 443. https://doi.org/10.3389/fphar.2019.00443.

Team members

Frédérique Sabourdy
Enseignant chercheur / University researcher
Stéphanie Brayer
Clinicien Chercheur / Researcher hospital practitioner
Marie Tosolini
Ingénieur de laboratoire / laboratory engineer
Lorry Carrié-Morella
Doctorant / PhD student
Patricia Clave
Technicien de laboratoire / Laboratory Technician
Stéphane Carpentier
Technicien de laboratoire / Laboratory Technician
Laura Leroy
Ingénieur de laboratoire / laboratory engineer
Bruno Segui
Chercheur statutaire / permanent scientist
Virginie Garcia
Ingénieur de laboratoire / laboratory engineer
Thierry Levade
Hospitalo-Universitaire / University teacher hospital practitioner
Alexandre Ghenassia
Chercheur Post-Doctorant / Post-Doc researcher
Nathalie Andrieu
Chercheur statutaire / permanent scientist
Matthieu Genais
Doctorant / PhD student
Elodie Mucher
Technicien de laboratoire / Laboratory Technician
Joëlle Riond
Chercheur statutaire / permanent scientist
Laurence Nieto
Enseignant chercheur / University researcher
Anne Montfort
Chercheur statutaire / permanent scientist
Mathieu Virazels
Doctorant / PhD student
Céline Colacios
Enseignant chercheur / University researcher
Carine Dufau
Doctorant / PhD student

Partnerships & funding

Centre de Recherches en Cancérologie de Toulouse

Centre de Recherches en Cancérologie de Toulouse (Oncopole)

Toulouse – FR

Nous contacter

05 82 74 15 75

Envie de rejoindre
L’équipe du CRCT ?

Pin It on Pinterest